Should Sangamo Therapeutics Inc. (NASDAQ:SGMO) enter your portfolio?


Sangamo Biosciences (NASDAQ:SGMO) traded in a range yesterday that spanned from a low of $6.05 to a high of $6.80. Yesterday, the shares gained 47.7%, which took the trading range above the 3-day high of $4.64 on volume of 10.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

The Sangamo Therapeutics’s Return on Assets were -40.90%%. At the close of the day, the stock reported a Market Cap of $491.54M in the Biotechnology Industry.

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions. Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend.

The company traded a total volume of 15,643,100, and the stock saw a change of 60.92% in the previous trading session. The company reported a 52-Week High of $-7.89% and a52-Week Low of $164.15%. The monthly Volatility of Sangamo Therapeutics, Inc. stood at 7.09%.

Sangamo Therapeutics, Inc. announced EPS of $-1.02. This represents a growth of -74.10% in EPS this year compared to what was reported last financial year and represents an overall growth of -7.50% over the past five year. The company is now projecting an EPS growth of -% in the next five years.

Sangamo Therapeutics, Inc.’s ownership was spread out with Insider Ownership amounting to 0.10% while Institutional Ownership amounted to 58.90%. Total insider transactions was 0.00% and total Institutional Transactions was 0.48%.

Return on Assets reported was -40.90%. Return on Equity for the financial year was -46.30% while Return on Investments was -51.80%. The company closed the year with a Total Debt/Equity of 0.03 out of which Long Term Debt/Equity was 0.03. Current and quick ratio amounted to 11.30 and 11.30 respectively.

The company has 70.22M shares outstanding at a price of $7.00 per share.

EPS growth reported for this year was -74.10%. For the past five years, the company has reported EPS growth of -7.50% with EPS growth for the next year projected to be -8.00%.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.